Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,922 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.
Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Among authors: ishida t. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.
Long-term outcome of breast-conserving therapy for breast cancer.
Shimauchi A, Nemoto K, Ogawa Y, Kakuto Y, Sakayauchi T, Takai Y, Ishida T, Ohuchi N, Hirakawa H, Kimura M, Yamada T, Takahashi S, Yamada S. Shimauchi A, et al. Among authors: ishida t. Radiat Med. 2005 Nov;23(7):485-90. Radiat Med. 2005. PMID: 16485539
Phase II study of capecitabine and trastuzumab combination chemotherapy in patients with HER2 overexpressing metastatic breast cancers resistant to both anthracyclines and taxanes.
Ishida T, Kiba T, Takeda M, Matsuyama K, Teramukai S, Ishiwata R, Masuda N, Takatsuka Y, Noguchi S, Ishioka C, Fukushima M, Ohuchi N. Ishida T, et al. Cancer Chemother Pharmacol. 2009 Jul;64(2):361-9. doi: 10.1007/s00280-008-0882-8. Epub 2008 Dec 12. Cancer Chemother Pharmacol. 2009. PMID: 19082596 Free PMC article. Clinical Trial.
Runx2 in human breast carcinoma: its potential roles in cancer progression.
Onodera Y, Miki Y, Suzuki T, Takagi K, Akahira J, Sakyu T, Watanabe M, Inoue S, Ishida T, Ohuchi N, Sasano H. Onodera Y, et al. Among authors: ishida t. Cancer Sci. 2010 Dec;101(12):2670-5. doi: 10.1111/j.1349-7006.2010.01742.x. Epub 2010 Oct 12. Cancer Sci. 2010. PMID: 20946121 Free PMC article.
Low dose capecitabine plus weekly paclitaxel in patients with metastatic breast cancer: a multicenter phase II study KBCSG-0609.
Taguchi T, Yamamoto D, Masuda N, Oba K, Nakayama T, Nagata T, Nomura M, Yoshidome K, Yoshino H, Matsunami N, Miyashita M, Furuya Y, Ishida T, Wakita K, Sakamoto J, Noguchi S; Kinki Breast Cancer Study Group (KBCSG). Taguchi T, et al. Among authors: ishida t. Cancer Chemother Pharmacol. 2013 Mar;71(3):741-7. doi: 10.1007/s00280-012-2068-7. Epub 2013 Jan 20. Cancer Chemother Pharmacol. 2013. PMID: 23334260 Clinical Trial.
[Adjuvant endocrine therapy for postmenopausal women].
Watanabe G, Ishida T, Ohuchi N. Watanabe G, et al. Among authors: ishida t. Nihon Rinsho. 2012 Sep;70 Suppl 7:636-40. Nihon Rinsho. 2012. PMID: 23350476 Japanese. No abstract available.
4,922 results